| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
OnKure Therapeutics, Inc.
13D/A
RPHM · 75974E103
|
1.6% |
1/21/2025
Event 1/16/2025
|
||||
| RiverVest Venture Fund III, L.P. | 0.2% | |||||
| RiverVest Venture Fund III (Ohio), L.P. | <0.1% | |||||
| RiverVest Venture Partners III (Ohio), LLC | <0.1% | |||||
| RiverVest Venture Partners III, L.P. | 0.2% | |||||
| RiverVest Venture Partners III, LLC | 0.2% | |||||
| RiverVest Venture Fund IV, L.P. | 1.3% | |||||
| RiverVest Venture Partners IV, L.P. | 1.3% | |||||
| RiverVest Venture Partners IV, LLC | 1.3% | |||||
| John P. McKearn, Ph.D. | 1.6% | |||||
| Jay Schmelter | 1.6% | |||||
| Thomas C. Melzer | 0.2% | |||||
| Niall O'Donnell, Ph.D. | 1.3% | |||||
|
Spruce Biosciences, Inc.
13D/A
SPRB · 85209E109
|
4.2% |
1/10/2025
Event 1/7/2025
|
||||
| RiverVest Venture Fund III, L.P. | 0.2% | |||||
| RiverVest Venture Fund III (Ohio), L.P. | 0.1% | |||||
| RiverVest Venture Partners III (Ohio), LLC | 0.1% | |||||
| RiverVest Venture Partners III, L.P. | 0.2% | |||||
| RiverVest Venture Partners III, LLC | 0.2% | |||||
| RiverVest Venture Fund IV, L.P. | 2.4% | |||||
| RiverVest Venture Partners IV, L.P. | 2.4% | |||||
| RiverVest Venture Partners IV, LLC | 2.4% | |||||
| John P. McKearn, Ph.D. | 4.2% | |||||
| Jay Schmelter | 4.2% | |||||
| Thomas C. Melzer | 0.2% | |||||
| Niall O'Donnell, Ph.D. | 2.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.